QuantiFERON-Monitor as Prognostic Marker of Mortality in Patients with Decompensated Cirrhosis: a Prospective Cohort Study.

Dongier, Alice; Louis, Edouard; Loly, Jean-Philippe; Dandoy, Pierre; Warling, Odile; Vijverman, Anne; Delwaide, Jean

doi:10.1016/j.clinre.2026.102776

Article (Scientific journals)

QuantiFERON-Monitor as Prognostic Marker of Mortality in Patients with Decompensated Cirrhosis: a Prospective Cohort Study.

Dongier, Alice; Louis, Edouard; Loly, Jean-Philippe et al.

2026 • In Clinics and Research in Hepatology and Gastroenterology, 50 (3), p. 102776

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/344743

DOI
10.1016/j.clinre.2026.102776

PubMed
41605414

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

QFM-Monitor-clinics and research in hep-26.pdf

Author postprint (1.08 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Acute-On-Chronic Liver Failure; Liver Cirrhosis; decompensated cirrhosis; immune dysfunction

Abstract :

[en] [en] BACKGROUND: Prognosis in decompensated cirrhosis is heterogeneous and may be influenced by cirrhosis-associated immune dysfunction. AIMS: To assess whether QuantiFERON-Monitor, a whole blood interferon-γ release assay, predicts short-term outcomes in patients with acute decompensated cirrhosis. METHODS: We conducted a prospective cohort study in two hospitals (March 2022-March 2023), enrolling 44 patients hospitalized for acute decompensated cirrhosis. QuantiFERON-Monitor testing measured interferon-γ release after immune stimulation during hospitalization. Patients were followed for 90 days for mortality, bacterial infection, and acute-on-chronic liver failure. Associations between interferon-gamma levels and outcomes were evaluated using Cox proportional hazards and logistic regression models. RESULTS: The median interferon-γ release was 56 IU/mL (1-366). Each 10 IU/mL increase was associated with a 12% relative reduction in 90-day risk of death or ACLF (HR 0.88, 95% CI 0.79-0.99; p=0.03). No deaths occurred in patients with Interferon-γ ≥ 100 IU/mL versus 39% mortality in those below (p=0.01). Interferon-γ levels were not significantly associated with infection or acute-on-chronic liver failure. Adding QuantiFERON-Monitor to the MELD-Na improved discrimination for early mortality or acute-on-chronic liver failure. CONCLUSIONS: Baseline interferon-γ release measured by the QuantiFERON-Monitor is a prognostic marker of short-term poor outcome in acute decompensated cirrhosis, reflecting cellular immune dysfunction. This assay may complement existing prognostic tools. Further validation with a larger cohort is required.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Dongier, Alice ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Loly, Jean-Philippe ; Université de Liège - ULiège > Département des sciences cliniques

Dandoy, Pierre; Université de Liège/CHU. Electronic address: Pierre.Dandoy@chuliege.be

Warling, Odile ; Université de Liège - ULiège > Département des sciences cliniques

Vijverman, Anne; CHR de la Citadelle de Liège. Electronic address: anne.vijverman@citadelle.be

Delwaide, Jean; Université de Liège/CHU. Electronic address: Jean.Delwaide@chuliege.be

Language :

English

Title :

QuantiFERON-Monitor as Prognostic Marker of Mortality in Patients with Decompensated Cirrhosis: a Prospective Cohort Study.

Publication date :

26 January 2026

Journal title :

Clinics and Research in Hepatology and Gastroenterology

ISSN :

2210-7401

eISSN :

2210-741X

Publisher :

Elsevier BV

Volume :

Issue :

Pages :

102776

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S2210740126000239?httpAccept=text/xml

Available on ORBi :

since 10 May 2026

Statistics

Number of views

94 (0 by ULiège)

Number of downloads

78 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Albillos, A., Martin-Mateos, R., Van der Merwe, S., Wiest, R., Jalan, R., Álvarez-Mon, M., Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol 19:2 (2022), 112–134.
Piano, S., Bunchorntavakul, C., Marciano, S., Rajender Reddy, K., Infections in cirrhosis. Lancet Gastroenterol Hepatol [Internet] 9:8 (2024), 745–757, 10.1016/S2468-1253(24)00078-5 Available from.
Trebicka, J., Bork, P., Krag, A., Arumugam, M., Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastroenterol Hepatol [Internet] 18:3 (2021), 167–180, 10.1038/s41575-020-00376-3 Available from.
Gardiner, B.J., Lee, S.J., Cristiano, Y., Levvey, B.J., Sullivan, L.C., Snell, G.I., et al. Evaluation of Quantiferon®-Monitor as a biomarker of immunosuppression and predictor of infection in lung transplant recipients. Transpl Infect Dis, 2020, 0–2.
Margeta, I., Mareković, I., Pešut, A., Zelenika, M., Dorotić, M., Mrnjec, I., et al. Evaluation of cell-mediated immune response by QuantiFERON Monitor Assay in kidney transplant recipients presenting with infective complications. Med (Baltim), 99(27), 2020, e21010.
Mian, M., Natori, Y., Ferreira, V., Selzner, N., Husain, S., Singer, L., et al. Evaluation of a Novel Global Immunity Assay to Predict Infection in Organ Transplant Recipients. Clin Infect Dis 66:9 (2018), 1392–1397.
Douglas, A.P., Yu, L., Sundararajan, V., Szer, J., Ritchie, D., Slavin, M.A., et al. The QuantiFERON Monitor® assay is predictive of infection post allogeneic hematopoietic cell transplantation. Transpl Infect Dis 22:3 (2020), 1–8.
Yong, M.K., Cameron, P.U., Spelman, T., Elliott, J.H., Fairley, C.K., Boyle, J., et al. Quantifying adaptive and innate immune responses in HIV-infected participants using a novel high throughput assay. PLoS One 11:12 (2016), 0–7.
Fernández-ruiz, M., Ruiz-merlo, T., Rodríguez-goncer, I., Caso, J.M., López-medrano, F., Parra, P., et al. Performance of a Global Functional Assay Based on Interferon- γ Release to Predict Infectious Complications and Cancer After Kidney Transplantation. Transpl Int 37:October (2024), 1–13.
Marx, S., Adam, C., Mihm, J., Weyrich, M., Sester, U., A Polyclonal Immune Function Assay Allows Dose-Dependent Characterization of Immunosuppressive Drug Effects but Has Limited Clinical Utility for Predicting Infection on an Individual Basis. Front Immunol 11:May (2020), 1–13.
Solidoro, P., Curtoni, A., Patrucco, F., Russo, E., Sidoti, F., Piccinini, G., et al. QuantiFERON ® Monitor Test as a Potential Tool for Stratifying Patients by Infection Risk and Tailoring Follow-Up Care in Lung Transplant Recipients : A Single-Center Retrospective Experience. Microorganisms 13:316 (2025), 1–13.
Sood, S., Haifer, C., Yu, L., Pavlovic, J., Churilov, L., Gow, P.J., et al. A novel immune function biomarker identifies patients at risk of clinical events early following liver transplantation. Liver Transpl, 2017, 1–35.
Yoon, E., Kim, K., Shin, S., Choi, S., Jang, J.H., Kim, S.J., et al. QuantiFERON monitor predicts early cytomegalovirus infection and viral burden in allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis(May), 2024, 1–8.
Boyer-Suavet, S., Cremoni, M., Dupeyrat, T., Zorzi, K., Brglez, V., Benzaken, S., et al. Functional immune assay using interferon-gamma could predict infectious events in end-stage kidney disease. Clin Chim Acta 502 (2020), 287–292 Mar 1.
Sood, S., Yu, L., Visvanathan, K., Angus, P.W., Gow, P.J., Testro, AG., Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients. World J Hepatol 8:35 (2016), 1569–1575.
Calandra, T., Cohen, J., The International Sepsis Forum Consensus Conference on definitions of infection in the intensive care unit. Crit Care Med 33:7 (2005), 1538–1548.
Moreau, R., Jalan, R., Gines, P., Pavesi, M., Angeli, P., Cordoba, J., et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterol [Internet] 144:7 (2013), 1426–1437.e9, 10.1053/j.gastro.2013.02.042 Available from.
Jalan, R., Saliba, F., Pavesi, M., Amoros, A., Moreau, R., Ginès, P., et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol [Internet] 61:5 (2014), 1038–1047, 10.1016/j.jhep.2014.06.012 Available from.
Trebicka, J., Fernandez, J., Papp, M., Caraceni, P., Laleman, W., Gambino, C., et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol 73:4 (2020), 842–854.
Gardiner, B.J., Lee, S.J., Cristiano, Y., Levvey, B.J., Sullivan, L.C., Snell, G.I., et al. Evaluation of Quantiferon®-Monitor as a biomarker of immunosuppression and predictor of infection in lung transplant recipients. Transpl Infect Dis 23:3 (2021), 1–9.
Sood, S., Cundall, D., Yu, L., Miyamasu, M., Boyle, J.S., Ong, S.Y., et al. A novel biomarker of immune function and initial experience in a transplant population. Transplantation 97:8 (2014), 50–51.
Irvine, K.M., Ratnasekera, I., Powell, E.E., Hume, DA., Casuses and consequences of innate immune dysfucntion in cirrhosis. Front Immunol 10:FEB (2019), 1–14.
Wasmuth, H.E., Kunz, D., Yagmur, E., Timmer-Stranghöner, A., Vidacek, D., Siewert, E., et al. Patients with acute on chronic liver failure display “sepsis-like” immune paralysis. J Hepatol 42:2 (2005), 195–201.
Angeli, P., Bernardi, M., Villanueva, C., Francoz, C., Mookerjee, R.P., Trebicka, J., et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69:2 (2018), 406–460.